Recently, Mu et al (2017) and Ku et al (2017) showed that prostate tumour progression to anti‐androgen resistance involves a mechanism named cellular lineage plasticity, in which the reprogramming transcription factors SOX2 and EZH2 play a role in inducing stemness, neuroendocrine phenotype and canonical androgen receptor signalling independence. This evidence concerns the gene SOX2 and prostate neoplasm.